A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer

International Journal of Cancer

Volumn 107, Issue 4, 2003, Pages 593-596

  Kuraoka, Kazuya ^a   Matsumura, Shunji ^a   Hamai, Yoichi ^a   Nakachi, Kei ^b   Imai, Kazue ^b   Matsusaki, Keisuke ^c   Oue, Naohide ^a   Ito, Reiko ^a   Nakayama, Hirofumi ^a   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^c Hofu Institute of Gastroenterology   (Japan)

Author keywords

Case control study; Gastric carcinoma; HER 2; Single nucleotide polymorphism; Transmembrane domain coding region

Indexed keywords

ADENINE; GUANINE; ISOLEUCINE; VALINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; JAPAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE NEU; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOGENESIS; STOMACH CARCINOMA;

ADENOCARCINOMA; AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GASTRIC MUCOSA; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RISK FACTORS; STOMACH NEOPLASMS;

EID: 0142117221     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11450     Document Type: Article

References (37)

1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-6.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229: 974-6.
3. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319: 226-30.
4. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
5. Hynes NE, Stern DF. The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
6. Peles E, Levy RB, Or E, Ullrich A, Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J 1991;10:2077-86.
7. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994;9:2109-23.
8. Stein D, Wu J, Fuqua SA, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 1994;13:1331-40.
9. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
10. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG. Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
11. ERBB2 expression and the gene amplification. Cancer Res 1990;50:8002-9.
12. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808.
13. Oda N, Tsujino T, Tsuda T, Yoshida K, Nakayama H, Yasui W, Tahara E. DNA ploidy pattern and amplification of ERBB and ERBB2 genes in human gastric carcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;58:273-7.
14. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, Kosaka T, Miwa K, Miyazaki L, Endou Y. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991;67:2914-8.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;44:783-92.
16. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58: 2825-31.
17. Nabholtz JM, Reese DM, Lindsay MA, Riva A. HER2-positive breast cancer: update on Breast Cancer International Research Group Trials. Clin Breast Cancer 2002;2(Suppl):S75-9.
18. Saya H, Ara S, Lee PS, Ro J, Hung MC. Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction. Mol Carcinog 1990;3:198-201.
19. Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 1990;5:237-9.
20. Sachse R, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Absence of activating mutations in the transmembrane domain of the c-erbB-2 protooncogene in human lung cancer. Jpn J Cancer Res 1992;83: 1299-303.
21. Papewalis J, Nikitin AY, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 1991;19:5452.
22. Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000;92: 412-7.
23. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE. Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 2001;61:8393-4.
24. Davis S, Mirick DK, Stevens RG. Residential magnetic field and the risk of breast cancer. Am J Epidemiol 2002;155:455-62.
25. Wang-Gohrke S, Chang-Claude J. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001;93:1657-9.
26. Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, Emi N, Tajima K. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2002;94: 1807-8.
27. McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, McLeod HL. C-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 2002;86:568-73.
28. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002;99:15937-40.
29. Yokozaki H. Distribution of germline BAT-40 poly-adenine tract microsatellite variants in the Japanese. Int J Mol 2000;6:445-8.
30. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
31. Chen LI, Webster MK, Meyer AN, Donoghue DJ. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. J Cell Biol 1997;137:619-31.
32. Cao H, Bangalore L, Bormann BJ, Stern DF. A subdomain in the transmembrane domain is necessary for p185neu* activation. EMBO J 1992;11:923-32.
33. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998;78:202-8.
34. Amundadottir LT, Leder P. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998;16:737-46.
35. Laferriere J, Houle F, Huot J. Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38. Ann NY Acad Sci 2002;973:562-72.
36. Ameyaw MM, Thronton N, McLeod HL. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000;92:1947.
37. Briscoe WT, Ray DB, Airhart JL, Ratliff AL, Shockley EA, Whetsell L. A new high frequency polymorphism in the HER-2/neu oncogene in normal tissue and breast tumors. Breast Cancer Res 1993;28:45-9.